期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

复方鳖甲软肝片联合西药治疗慢性乙型肝炎150例 被引量：3

下载PDF
导出
摘要 目的:观察慢性乙型肝炎患者采用复方鳖甲软肝片联合阿德福韦酯治疗后HBV-DNA载量、血清IL-2、sIL-2R、IL-4、TNF-α含量变化。方法:对150例HBeAg阳性乙型肝炎患者采用复方鳖甲软肝片联合阿德福韦酯治疗48周,观察患者治疗前后HBV-DNA载量变化与血清IL-2、sIL-2R、IL-4、TNF-α含量变化。结果:150例患者48周HBV-DNA载量对数值为3.41±0.84,较治疗前明显下降(P<0.01);血清IL-2含量较治疗前显著增高(P<0.05),sIL-2R、IL-4、TNF-α含量显著降低,与治疗前比较有统计学意义(P<0.05)。结论:慢性乙型肝炎患者经过48周治疗后,发现复方鳖甲软肝片联合阿德福韦酯能够有效地抑制HBV-DNA的复制,降低血清sIL-2R、IL-4、TNF-α的水平。
作者 王喜梅
机构地区 河南省洛阳东方医院消化科
出处 《陕西中医》 2011年第7期856-858,共3页 Shaanxi Journal of Traditional Chinese Medicine
关键词 肝炎 乙型 慢性/中西医结合疗法 @复方鳖甲软肝片/治疗应用
分类号 R575.1 [医药卫生—消化系统]
  • 相关文献

参考文献6

  • 1Zeng M,Man Yao Getal. A double blind randomized trial of adefovie diFlivoxil in chinese subjects with HBeAg- positive chronic hepatitis B [J ]. Hepatology, 2006,44 ( 2 ) : 108-116.
  • 2病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62. 被引量：1828
  • 3Pawlowska M,Halota W,Smukalska E,ct al. Serum IL-2 and sI2R COncentrafionin childrenwith chronic hepatitis B [J]. PolMerkurLkarski,2005,18(103): 33-35.
  • 4Sheron N,LauJN,HofmannJ,et al. DOse dependent increase in plasma interleukin-6 after recombinant tumor necrosis factor infusion in hunans . Clin Exp Immunol, 1990, 82..427-428 ;.
  • 5Patrick M,Ting-Tsung C,Seng GL,et al. Adefovir dipivoxil : the treatment of hepatitis B e antigen-positive chronic hepatitis B[J]Engl J Med,2003o 348(9):808-816.
  • 6曾民德,茅益民,姚光弼,周霞秋,王豪,徐道振,姚集鲁,侯金林,王宇明,任红,陈亚岗,牛俊奇,王耀宗.阿德福韦酯治疗HBeAg阳性的中国慢性乙型病毒性肝炎患者52周的多中心临床研究[J].中华传染病杂志,2005,23(6):387-394. 被引量：164

二级参考文献19

  • 1Hadziyannis S,Tassopoulos N,Chang TT,et al.Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long-term safety and efficacy study.J Hepatol,2004,40(Suppl 1):17 (Abstract 46).
  • 2Hadziyannis SJ,Papatheodoridis GV.Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.Expert Rev Anti Infect Ther,2004,2:475-483.
  • 3Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348:808-816.
  • 4Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med,2003,348:800-807.
  • 5Cullen JM,Li DH,Brown C,et al.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.Antimicrob Agents Chemother,2001,45:2740-2745.
  • 6Delmas J,Schorr O,Jamard C,et al.Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Antimicrob Agents Chemother,2002,46:425-433.
  • 7Werle-Lapostolle B,Bowden S,Locarnini S,et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.Gastroenterology,2004,126:1750-1758.
  • 8Lok AS,McMahon BJ.Chronic hepatitis B:update of recommendations.Heptology,2004,39:857-861.
  • 9Qi X,Snow A,Thibault V,et al.Long-term incidence of Adefovir Dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy.Hepatol,2004,40(Suppl 1):20 (Abstract 57).
  • 10Westland CE,Yang H,Delaney WE 4th,et al.Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.Hepatology,2003,38:96-103.

共引文献1983

同被引文献47

  • 1周光德,李文淑,赵景民,孙艳玲,潘登,杨建法,郭顺根,张玲霞,陈菊梅.复方鳖甲软肝片抗肝纤维化机制的临床病理研究[J].解放军医学杂志,2004,29(7):563-564. 被引量：88
  • 2Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
  • 3无.慢性乙型肝炎防治指南[J].实用肝脏病杂志,2006,9(1):8-18. 被引量：825
  • 4张建春,胡娟.阿徳福韦酯联合苦参素胶囊治疗悝性乙型肝炎临床研究[J].Chinese Hepatoloy.2010,15(1) :34-35.
  • 5Westland CE, Yang H, Delaney WE, et al. Activity of adeforvir dip-ivoxil against all patterns of lamivudine-resistant hepatitis B viruses inpatient s[J].J Viral Hepatitis,2005,12(1):67.
  • 6^ellicelli AM, Barbaro G, Franca villa R, et al. Adefovir and lamivu-dine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical orvirologic resistance to lamivudine: a retrospective, multicenter, non-ran-domized,open-label studyCj) .Clin Ther,2008,30(2) ;317-323.
  • 7QAQ ISH R B, MATTES K A, R ITCH IE D J. Adefovir dipivoxil and antiviral ent for the treatment of hepatitis B virus infection[J].CIin Ther, 2003,25(0):3084- 3099.
  • 8Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity[J]. Vaccine,2012,30 (12):2212-2219.
  • 9Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 cause of death for 20 age gropes in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010 [J]. Lancet,2012,380 (9859):2095- 2128.
  • 10葛钧波,徐永健.内科学[M].8版.北京.人民卫生出版社.2013:419-428.

引证文献3

二级引证文献12

陕西中医
2011年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部